There are 10 products in the pipeline for microbial keratitis, an ocular infection...
EyePoint Pharmaceuticals reports positive data for second YUTIQ trial
EyePoint Pharmaceuticals has reported positive topline 36-month follow-up data from the second Phase III trial of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18mg three-year micro-insert.
ReNeuron’s hRPC stem cell therapy yields positive results
ReNeuron Group has reported positive long-term efficacy data from the ongoing Phase I/II clinical trial of human retinal progenitor cell (hRPC) stem cell therapy in patients with retinitis pigmentosa (RP).
Regeneron reports two-year diabetic retinopathy data of Eylea
Regeneron Pharmaceuticals has reported positive two-year data of Eylea (aflibercept) from the Phase III PANORAMA clinical trial in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study
Aldeyra Therapeutics has enrolled the first patient in a Phase III INVIGORATE clinical trial being conducted to assess reproxalap for the treatment of allergic conjunctivitis.
Neuroptika enrols first patient for dry eye disease trial
Neuroptika has enrolled the first patient in a Phase II clinical trial of NRO-1 for the treatment of dry eye disease.
Gemini Therapeutics starts patient enrolment for AMD study
Gemini Therapeutics has commenced patient enrolment in its Phase I study of GEM103 for the treatment of dry age-related macular degeneration (AMD).
Aldeyra Therapeutics enrols first patient in Phase III GUARD study
Aldeyra Therapeutics has started enrolling patients in the Phase III GUARD clinical trial of ADX-2191 to prevent proliferative vitreoretinopathy (PVR), a rare retinal disease.
ProQR doses first patient in Aurora trial of retinal disease therapy
ProQR Therapeutics has dosed the first patient in a Phase I/II Aurora clinical trial to evaluate QR-1123 in patients with autosomal dominant retinitis pigmentosa (adRP).
Biogen completes enrolment in STAR trial of timrepigene emparvovec
Biogen has completed enrolment in the Phase III STAR clinical trial of timrepigene emparvovec (BIIB111/AAV2-REP1) to treat choroideremia (CHM), a rare, degenerative, X-linked retinal disorder.
Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)
Beovu® (brolucizumab) is an anti-vascular endothelial growth factor (anti-VEGF) drug indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).